Combination of Monoclonal Antibody and Dexamethasone in Myeloma Treatment

The multiple myeloma field is rapidly evolving, with exciting developments in strategies for the treatment of smoldering myeloma, relapsed/refractory (R/R) disease, and transplant-eligible patients. The impact of measurable residual disease (MRD) negativity in the clinical decision-making process for patients with multiple myeloma remains a hotly debated topic among the experts.

In this podcast, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, chairs a discussion with Francesca Gay, MD, PhD, University of Turin, Turin, Italy, and Saad Usmani, MD, FACP, Levine Cancer Institute & Atrium Health, Charlotte, NC, on the most important updates and latest research evidence in multiple myeloma.

The post The Myeloma Sessions: smoldering myeloma, MRD evaluation, R/R disease & transplant-eligible patients appeared first on VJHemOnc.